bezlotoxumab
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Clostridium difficile infection (CDI) is a leading nosocomial disease estimated to cause nearly half a million cases in the…
Abstract Background Bezlotoxumab is a human monoclonal antibody against Clostridium difficile toxin B indicated to prevent C…
Background
Clostridium difficile infection (CDI) is the most commonly recognized cause of recurrent diarrhea. Bezlotoxumab…
Clostridium difficile infection (CDI) is the most common health care-acquired infection associated with high hospital…
Background Clostridium difficile is the most common cause of infectious diarrhea in hospitalized patients. Recurrences are common…
During the past decade, the incidence and severity of Clostridium difficile infection (CDI) have significantly increased, leading…
Bezlotoxumab (Zinplava™) is a human monoclonal antibody against Clostridium difficile toxin B developed by Merck & Co. In October…
Background: Bezlotoxumab is a neutralizing antibody targeting toxin B of Clostridium difficile. Results: The structure of…
ABSTRACT Clostridium difficile infection (CDI) represents the most prevalent cause of antibiotic-associated gastrointestinal…